TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02640469

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine with water rinse
Description: This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine without water rinse
Description: Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
Study: NCT01149460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Test 1000 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Reference Listed Valacyclovir 1000 mg Tablet
Study: NCT01531036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Ultrasound elastography by means of shear wave propagation into breast tissue
Description: Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
Study: NCT02640131

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biomedical Component
Description: Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
Study: NCT02640469

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine + sterillium hand rub
Description: Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
Study: NCT02448810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 + infusional 5-FU/LV
Description: Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 + panitumumab
Description: Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 + 5-FU/LV
Description: Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 + panitumumab
Description: Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: * Investigator's choice~* Dose according to drug label

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: * Investigator's choice~* Dose according to drug label~* Choice includes panitumumab in KRAS \&NRAS wt group only
Study: NCT03327597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow-up 1
Description: Participants receive routine care outside the bounds of the trial. No further work-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health and Quality of Life questionnaire
Description: Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health and Quality of Life questionnaire
Description: Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health and Quality of Life questionnaire
Description: Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health and Quality of Life questionnaire
Description: Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health and Quality of Life questionnaire
Description: Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health and Quality of Life questionnaire
Description: Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up or treatment.
Description: Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow-up 2
Description: Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow-up 3
Description: Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical follow-up control
Description: Control clinical visit
Study: NCT02883842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
Study: NCT01268150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
Study: NCT03276793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Patients will undergo an MRI scan
Study: NCT02640131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomedical Component
Description: Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Component
Description: Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
Study: NCT03757117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feminizing hormone therapy
Description: Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation
Description: Transgender women community peer navigation
Study: NCT01808170

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian cystectomy
Description: will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cyst deroofing
Description: will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
Study: NCT03345082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: Intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: Intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injection

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: ranibizumab
Description: Intravitreal injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham intravitreal injection
Description: Sham (mock) intravitreal injection
Study: NCT02475993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMART app
Description: Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
Study: NCT03062436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopping the standard drug therpy
Description: Stopping the standard drug therapy of CML patients and monitoring their treatment free remission status
Study: NCT03881254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Autologous Homologous Skin Construct
Description: Application of a autologous human derived skin polar units
Study: NCT03062436

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative bcrabl recording every month for first 6 months
Description: Monthly recording of quantitative bcrabl by RQPCR on patients peripheral blood derived RNA. RQPCR will have minimum sensitivity of log4.5
Study: NCT04537156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nonavalent HPV vaccine
Description: Nonavalent HPV vaccine (270μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent HPV vaccine
Description: Bivalent HPV vaccine (60μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study: NCT03439072

Intervention type: DRUG
Group type: OTHER
Intervention: G-Pen
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector

Intervention type: DRUG
Group type: OTHER
Intervention: G-Pen
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector

Intervention type: DRUG
Group type: OTHER
Intervention: Lilly Glucagon
Description: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])

Intervention type: DRUG
Group type: OTHER
Intervention: Lilly Glucagon
Description: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])
Study: NCT01417988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Empiric TB treatment
Description: Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART only arm
Description: ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
Study: NCT04124419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Evolve System
Description: EMS and RF Treatment
Study: NCT02125422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly tDCS
Description: Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
Study: NCT00959049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL's Influenza Virus Vaccine (Afluria)
Description: 0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL's Influenza Virus Vaccine (Afluria)
Description: 0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL's Influenza Virus Vaccine (Afluria)
Description: 0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine (Fluzone)
Description: 0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine (Fluzone)
Description: 0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine (Fluzone)
Description: 0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
Study: NCT03982810

Intervention type: DRUG
Intervention: Antibiotics
Description: Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
Study: NCT03497702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60mg/m2 IV every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2 IV every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 IV every 3 weeks for 4 cycles
Study: NCT03881254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Outer Dressing Applicaiton
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Outer Dressing Applicaiton
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing
Study: NCT03497702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg once daily preoperably

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: 3.75 mg SC every 4 weeks for premenopausal patients
Study: NCT01752179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinesio Tape : Width 5cm ,Length 35cm Y shape
Description: In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~1. stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~2. puts the base of tape over the contralateral of sacrum with no tension.~3. attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~4. attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application.
Study: NCT03917901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Training
Description: Computerized Single-Session Anxiety Sensitivity Reduction Program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Control
Description: Computerized Single-Session Health Information Control
Study: NCT03992872

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chikungunya
Description: Virus Like Particle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chikungunya
Description: Virus Like Particle
Study: NCT03076151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus monohydrate (ADOPORT®)
Description: Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
Study: NCT02556047

Intervention type: DEVICE
Group type: OTHER
Intervention: Star Intradermal Safety Device
Description: Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N\&S
Study: NCT02510924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Description: tracheal intubation with Airtraq sp vs Airtraq mobile

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: tracheal intubation with Airtraq sp vs Airtraq mobile
Study: NCT03276793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral testing
Description: Patients will complete a series of cognitive tasks
Study: NCT02326675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice
Description: This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Solution
Description: This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
Study: NCT03295500

Intervention type: RADIATION
Intervention: Dose fraction forms
Description: The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.

Intervention type: RADIATION
Intervention: Dose fraction forms
Description: The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.

Intervention type: RADIATION
Intervention: Dose fraction forms
Description: The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
Study: NCT01104155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eribulin mesylate + erlotinib
Description: 21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eribulin mesylate + erlotinib
Description: 28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
Study: NCT02378727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active: Comparator Loss Of Resistance Syringe
Description: Lumbar epidural procedure utilizing Loss of Resistance Syringe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: CompuFlo® Epidural System
Description: CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space